MedPath

Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy

Phase 4
Completed
Conditions
Diabetic Nephropathy
Registration Number
NCT00311870
Lead Sponsor
Steno Diabetes Center Copenhagen
Brief Summary

The aim of the study was to compare the renoprotective effect of a long acting calcium antagonist (nisoldipine) with an angiotensin converting enzyme inhibitor (lisinopril)in type 1 diabetic patients with diabetic kidney disease. In total, 51 patients were randomised to treatment with one of these drugs for 4 years. Changes in kidney function, blood pressure and urinary excretion of albumin were measured every 6 months

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
52
Inclusion Criteria
  • diabetic nephropathy, type 1 diabetes, hypertension
Exclusion Criteria
  • child bearing potential, non-diabetic kidney disease, malignancy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
change in glomerular filtration rate from study start to study end
Secondary Outcome Measures
NameTimeMethod
change in urinary albumin excretion rate
blood pressure response

Trial Locations

Locations (1)

Steno Diabetes Center

🇩🇰

Gentofte, Denmark

© Copyright 2025. All Rights Reserved by MedPath